{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:32:26Z","timestamp":1791307946184,"version":"4.3.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T00:00:00Z","timestamp":1283212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/nrclinonc.2010.141","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T14:03:53Z","timestamp":1283263433000},"page":"600-603","source":"Crossref","is-referenced-by-count":34,"title":["Complete molecular response in CML after p210 BCR\u2013ABL1-derived peptide vaccination"],"prefix":"10.1038","volume":"7","author":[{"given":"Monica","family":"Bocchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Defina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Crupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"BFnrclinonc2010141_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann, R., Hochhaus, A. & Baccarani, M. Chronic myeloid leukaemia. Lancet 370, 342\u2013350 (2007).","journal-title":"Lancet"},{"key":"BFnrclinonc2010141_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/sj.leu.2404983","volume":"22","author":"MC Muller","year":"2008","unstructured":"Muller, M. C.  et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22, 96\u2013102 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc2010141_CR3","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","volume":"111","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian, H., Shiffer, C., Jones, D. & Cortes, J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111, 1774\u20131780 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2010141_CR4","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2007","unstructured":"Druker, B. J.  et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2010141_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","volume":"6","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Imatinib and beyond\u2014exploring the full potential of targeted therapy for CML. Nat. Rev. Clin. Oncol. 6, 535\u2013543 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc2010141_CR6","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade, H.  et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358\u20133363 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2010141_CR7","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"F Bonifazi","year":"2001","unstructured":"Bonifazi, F.  et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98, 3074\u20133081 (2001).","journal-title":"Blood"},{"issue":"Suppl. 2","key":"BFnrclinonc2010141_CR8","first-page":"S45","volume":"81","author":"DW Beelen","year":"2002","unstructured":"Beelen, D. W. & Schaefer, U. W. Allogeneic stem cell transplants in chronic myeloid leukemia. Ann. Hematol. 81 (Suppl. 2), S45\u2013S46 (2002).","journal-title":"Ann. Hematol."},{"key":"BFnrclinonc2010141_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus, A.  et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054\u20131061 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2010141_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot, P.  et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58\u201360 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2010141_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia, M.  et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657\u2013662 (2005).","journal-title":"Lancet"},{"key":"BFnrclinonc2010141_CR12","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","volume":"21","author":"JM Rojas","year":"2007","unstructured":"Rojas, J. M., Knight, K., Wang, L. & Clark, R. E. Clinical evaluation of BCR\u2013ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21, 2287\u20132295 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc2010141_CR13","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1002\/cncr.24468","volume":"115","author":"N Jain","year":"2009","unstructured":"Jain, N.  et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 115, 3924\u20133934 (2009).","journal-title":"Cancer"},{"key":"BFnrclinonc2010141_CR14","first-page":"648","volume":"114","author":"M Bocchia","year":"2009","unstructured":"Bocchia, M.  et al. BCR\u2013ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial. ASH Annual Meeting Abstracts 114, 648 (2009).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"BFnrclinonc2010141_CR15","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","volume":"114","author":"JP Radich","year":"2009","unstructured":"Radich, J. P. How I monitor residual disease in chronic myeloid leukemia. Blood 114, 3376\u20133381 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2010141_CR16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert, A.  et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol. 28, 1429\u20131435 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2010141_CR17","first-page":"3209","volume":"112","author":"M Bocchia","year":"2008","unstructured":"Bocchia, M.  et al. CMLVAX100 peptide vaccinations induce peptide specific \u201ccytotoxic\u201d CD4+ T Cells (CD4+CTLs) in chronic myeloid leukemia patients: new insights about peptide vaccine-mediated antitumor response. ASH Annual Meeting Abstracts 112, 3209 (2008).","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.141","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:04:35Z","timestamp":1684469075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BFnrclinonc2010141"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2010.141","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}